This renewal application for the tPPG Vascular Sub-Phenotypes of Lung Disease extends our drug discoveries over the last 4 years to three clinical trials in each of our three Projects. We will initiate a Personalized Medicine approach to the study and treatment of pulmonary vascular disease, focusing on how a patient's diet, microbiome, and development of metabolic syndrome will contribute to pulmonary vascular disease and its therapy. In our tPPG we hypothesize that sub-phenotypes of common diseases, such as the metabolic syndrome, have a profound influence on pulmonary vascular disease symptoms, prognosis, and response to therapy. The overarching translational goal of this program is to define the common mechanistic and therapeutic pathways of pulmonary hypertension (PH) in the context of major lung and systemic diseases, such as the metabolic syndrome - and target this biology with new drug strategies stemming from the productive first years of this project. In the initial funding period we developed a) new pre-clinical mouse and rat models of PH in the setting of metabolic syndrome, b) characterized a major signaling paradigm in biology linking dietary nitrate and the microbiome to the reactive nitrogen species, nitrite and nitrated fatty acids (NO2- FA), all of which modulate PH in pre-clinical models, and c) developed promising new GMP drug strategies evolving from this pathway that exhibit strong safety profiles in humans. In this tPPG renewal we have translated these discoveries into sub-phenotype-targeted drugs and phase 2 clinical trials. Our tPPG was designed as a drug development pipeline where the drugs across all Projects were tested in pre-clinical models for safety and efficacy, and then developed based on success. Successful drugs moved to GMP formulation and phase 1 safety studies in collaboration with the NIH pharmacy development service and by partnership with biotechnology companies. Our overarching strategy was to develop an internal competition between Projects to identify the best drugs for clinical trial evaluation in the second phase of th tPPG. To this end we have completed pre-clinical studies and human phase 1 safety, PK/PD and early proof of concept trials with inhaled and oral preparations of nitrite and nitrate, and boh intravenous and oral formulations of 10-nitro-oleic acid (NO2-OA), strongly positioning our group for the next translational directive of the tPPG mechanism - to move these discoveries to phase 2 trials, commercialization and improved patient care. Based on extensive data generated over the last cycle of this tPPG, we hypothesize that new nitrate-nitrite-NO-NO2-FA therapies target both the metabolic syndrome and the pulmonary vasculature, and will limit disease progression in patients with this sub-phenotype. In this regard, our proposed translational research plan will aggressively address this unmet need by employing nitrate, nitrite and NO2-FA pharmacologic strategies that pleiotropically target the dysmetabolic, pro-proliferative and pro-inflammatory milieu of PH Narrative: In our tPPG, we have proposed that pulmonary vascular disease is a relatively under-studied, but important sub-phenotype in the broader setting of chronic heart and lung diseases, increasing disease severity and complicating therapy. Pathological pulmonary vascular remodeling occurs in subsets of patients in the setting of left heart diastolic dysfunction, the metabolic syndrome, and is a secondary event in advanced lung diseases. The development of pulmonary hypertension (PH) in these settings is further modulated by host genetics, diet, and microbiome and the development of the most effective specific therapy likely requires dual targeting of the underlying conditions, such as metabolic syndrome and the pulmonary vascular sub-phenotype. Based on extensive data generated over the last cycle of this tPPG, we hypothesize that new nitrate, nitrite, and nitro-fatty acid based therapies, that have now successfully advanced through human phase 1 safety testing, will target both the metabolic syndrome and the pulmonary vasculature, to limit disease progression in patients with this PH sub-phenotype.

Public Health Relevance

In our tPPG, we have proposed that pulmonary vascular disease is a relatively under-studied, but important sub-phenotype in the broader setting of chronic heart and lung diseases, increasing disease severity and complicating therapy. Pathological pulmonary vascular remodeling occurs in subsets of patients in the setting of left heart diastolic dysfunction, the metabolic syndrome, and is a secondary event in advanced lung diseases. The development of pulmonary hypertension (PH) in these settings is further modulated by host genetics, diet, and microbiome and the development of the most effective specific therapy likely requires dual targeting of the underlying conditions, such as metabolic syndrome and the pulmonary vascular sub-phenotype. Based on extensive data generated over the last cycle of this tPPG, we hypothesize that new nitrate, nitrite, and nitro-fatty acid based therapies, that have now successfully advanced through human phase 1 safety testing, will target both the metabolic syndrome and the pulmonary vasculature, to limit disease progression in patients with this PH sub-phenotype.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL103455-08
Application #
9481710
Study Section
Special Emphasis Panel (ZHL1)
Program Officer
Xiao, Lei
Project Start
2011-06-01
Project End
2021-04-30
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
8
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Raghu, Vineet K; Ramsey, Joseph D; Morris, Alison et al. (2018) Comparison of strategies for scalable causal discovery of latent variable models from mixed data. Int J Data Sci Anal 6:33-45
Kudryashova, Tatiana V; Shen, Yuanjun; Pena, Andressa et al. (2018) Inhibitory Antibodies against Activin A and TGF-? Reduce Self-Supported, but Not Soluble Factors-Induced Growth of Human Pulmonary Arterial Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension. Int J Mol Sci 19:
Freeman, Bruce A; O'Donnell, Valerie B; Schopfer, Francisco J (2018) The discovery of nitro-fatty acids as products of metabolic and inflammatory reactions and mediators of adaptive cell signaling. Nitric Oxide 77:106-111
Villacorta, Luis; Minarrieta, Lucia; Salvatore, Sonia R et al. (2018) In situ generation, metabolism and immunomodulatory signaling actions of nitro-conjugated linoleic acid in a murine model of inflammation. Redox Biol 15:522-531
Remy, Kenneth E; Cort├ęs-Puch, Irene; Solomon, Steven B et al. (2018) Haptoglobin improves shock, lung injury, and survival in canine pneumonia. JCI Insight 3:
Rom, Oren; Khoo, Nicholas K H; Chen, Y Eugene et al. (2018) Inflammatory signaling and metabolic regulation by nitro-fatty acids. Nitric Oxide :
D'Amore, Antonio; Fazzari, Marco; Jiang, Hong-Bin et al. (2018) Nitro-Oleic Acid (NO2-OA) Release Enhances Regional Angiogenesis in a Rat Abdominal Wall Defect Model. Tissue Eng Part A 24:889-904
Schopfer, Francisco J; Vitturi, Dario A; Jorkasky, Diane K et al. (2018) Nitro-fatty acids: New drug candidates for chronic inflammatory and fibrotic diseases. Nitric Oxide 79:31-37
Farkas, Daniela; Thompson, A A Roger; Bhagwani, Aneel R et al. (2018) Toll-like Receptor 3 is a Therapeutic Target for Pulmonary Hypertension. Am J Respir Crit Care Med :
Goncharov, Dmitry A; Goncharova, Elena A; Tofovic, Stevan P et al. (2018) Metformin Therapy for Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction versus Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 198:681-684

Showing the most recent 10 out of 182 publications